The newly built farm uses a high-fat, high-cholesterol diet to give animals heart disease and diabetes to help medical researchers find treatments.
Under the agreement, Lilly will pay Sigilon Therapeutics up to $410 million if the technology hits certain milestones.
The funds includes $7.6 million to study early-onset Alzheimer’s disease, $5.2 million to fund a clinical and translational sciences institute, and $4.8 million to fund epidemiologic databases to evaluate AIDS care in Africa.
The 5-year-old Carmel biotech has won plenty of attention from Wall Street and has secured more than $100 million through licensing deals and a stock offering to help fund expensive clinical trials.
The study will focus on early-onset Alzheimer’s disease, which are about 5 percent of patients.
In a quest to end cookie-cutter health care, U.S. researchers are getting ready to recruit more than 1 million people for an unprecedented study to learn how our genes, environments and lifestyles interact—and to finally customize ways to prevent and treat disease. Why does one sibling get sick but not another? Why does a drug […]
The federal agency says the Indianapolis doctor studying Pfizer’s Chantix last year failed to keep accurate records and used patients who didn’t meet the trial requirements.
Vice President Mike Pence may have just picked another fight with pharmaceutical companies—one that doesn’t involve drug prices.
One of the bill’s author said it is designed to help parents who are “up against a wall,” and he stressed that it should not be confused as a first step to medical marijuana legalization in the state.
A small Carmel-based biotech firm has signed a deal with international drug company Allergan Plc that is worth at least $50 million and could grow to more than $2 billion under the best-case scenario.
The National Institute on Aging is awarding $25 million to the Alzheimer's Disease Precision Models Center, a joint project of the Indiana University School of Medicine in Indianapolis and The Jackson Laboratory in Bar Harbor.
The Indiana University School of Medicine got the donation from the children of Indianapolis real estate developer Sidney Eskenazi. The endowed fund will be used to recruit a cancer researcher to Simon Cancer Center.
The money will be awarded from IU’s Grand Challenges Program, a new push that is designed to tackle “major and large-scale problems facing humanity” that can only be addressed by multidisciplinary research teams.
The Indiana Biosciences Research Institute, set up just three years ago, announced Wednesday morning that it has been awarded grants of $80 million from the Lilly Endowment and $20 million from the Eli Lilly and Co. Foundation.